Following the invitation of Sindusfarma (Syndicate of the Pharmaceutical Products Industry in the State of São Paulo) and Anvisa (Brazilian Health Regulatory Agency), stakeholders met to discuss Brazil’s challenges with advanced therapies. The two days with participation of politicians, scientists, clinicians and policy experts were organised in a first step to assess the current status of funding advanced therapies and treatment for rare diseases; then to develop concrete strategies for stakeholders on how to organise themselves to overcome these challenges. The choice of the venue at the Health Regulatory Agency’s office in the capital of Brazil highlights the awareness and will to collaborate among the different actors of the Brazilian health care system.

Dr. Meriem Bouslouk-Marx presented a paper with the title “How does Germany deal with gene therapies?”.

From left to right: André Cézar Medici, Gabriela Tannus and Meriem Bouslouk-Marx. Photo by © Francisco Brasil

More information: GENE AND ADVANCED THERAPIES: Creating Value in the Patient Journey and the Health System